Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Current Investments (2016 - 2026)

Gyre Therapeutics has reported Cash & Current Investments over the past 16 years, most recently at $52.4 million for Q4 2025.

  • Quarterly Cash & Current Investments rose 96.66% to $52.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.4 million through Dec 2025, up 96.66% year-over-year, with the annual reading at $52.4 million for FY2025, 96.66% up from the prior year.
  • Cash & Current Investments was $52.4 million for Q4 2025 at Gyre Therapeutics, up from $46.8 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $131.0 million in Q1 2021 and troughed at $2.2 million in Q3 2023.
  • The 5-year median for Cash & Current Investments is $28.2 million (2024), against an average of $39.8 million.
  • Year-over-year, Cash & Current Investments plummeted 90.35% in 2023 and then surged 1026.21% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $49.4 million in 2021, then plummeted by 48.99% to $25.2 million in 2022, then crashed by 57.97% to $10.6 million in 2023, then soared by 151.92% to $26.7 million in 2024, then surged by 96.66% to $52.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cash & Current Investments are $52.4 million (Q4 2025), $46.8 million (Q3 2025), and $46.5 million (Q2 2025).